Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca , Boston , USA.
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca , Gothenburg , Sweden.
Expert Opin Drug Deliv. 2019 Nov;16(11):1149-1167. doi: 10.1080/17425247.2019.1663822. Epub 2019 Sep 12.
: The delivery of nucleic acid therapeutics through non-viral carriers face multiple biological barriers that reduce their therapeutic efficiency. Despite great progress, there remains a significant technological gap that continues to limit clinical translation of these nanocarriers. A number of polymeric materials are being exploited to efficiently deliver nucleic acids and achieve therapeutic effects. : We discuss the recent advances in the polymeric materials for the delivery of nucleic acid therapeutics. We examine the use of common polymer architectures and highlight the challenges that exist for their development from bench side to clinic. We also provide an overview of the most notable improvements made to circumvent such challenges, including structural modification and stimuli-responsive approaches, for safe and effective nucleic acid delivery. : It has become apparent that a universal carrier that follows 'one-size' fits all model cannot be expected for delivery of all nucleic acid therapeutics. Carriers need to be designed to exhibit sensitivity and specificity toward individual targets diseases/indications, and relevant subcellular compartments, each of which possess their own unique challenges. The ability to devise synthetic methods that control the molecular architecture enables the future development that allow for the construction of 'intelligent' designs.
: 通过非病毒载体传递核酸治疗面临多种生物屏障,降低了它们的治疗效率。尽管取得了巨大进展,但仍存在显著的技术差距,这继续限制了这些纳米载体的临床转化。许多聚合材料正在被开发用于有效传递核酸并实现治疗效果。: 我们讨论了用于核酸治疗传递的聚合材料的最新进展。我们考察了常见聚合物结构的使用,并强调了它们从实验室到临床发展所存在的挑战。我们还概述了为了安全有效地传递核酸而克服这些挑战所做的最显著的改进,包括结构修饰和刺激响应方法。: 显然,不能期望有一种通用的载体能够适用于所有核酸治疗的传递。载体的设计需要对个别靶点疾病/适应症和相关的亚细胞区室表现出敏感性和特异性,每个区室都有其独特的挑战。设计能够控制分子结构的合成方法的能力为未来的发展提供了可能,从而能够构建“智能”设计。